KELSEY BAUER: Open Payments
NPI 1114681889 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 56 payments from 10 companies in 2025. Trend: 2023 $271 · 2024 $651 · 2025 $962
Food & beverage: $962
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $213 |
| ABBVIE INC. | 12 | $165 |
| E.R. Squibb & Sons, L.L.C. | 11 | $153 |
| Otsuka America Pharmaceutical, Inc. | 6 | $112 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| Alkermes, Inc. | 4 | $78 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Indivior Inc. | 3 | $46 |
| Lundbeck LLC | 2 | $41 |
| Axsome Therapeutics, Inc. | 1 | $22 |
Products named: CAPLYTA, COBENFY, VRAYLAR, REXULTI, ARISTADA, FANAPT, Qelbree, SUBLOCADE.
Industry payments across IA — which companies pay providers there.
